21 Apr 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
17 Apr 2025 by admin in UncategorizedComments Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
17 Apr 2025 by admin in UncategorizedComments Adicet Bio Appoints Michael Grissinger to the Board of Directors
07 Apr 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Haley Laken, Ph.D., as Chief Scientific Oficer April 7, 2025
07 Apr 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Laura Sepp-Lorenzino, Ph.D., to Its Board of Directors
20 Mar 2025 by admin in UncategorizedComments Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
17 Mar 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Oficer and Chief Medical Officer
10 Jan 2025 by admin in UncategorizedComments Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD
07 Jan 2025 by admin in UncategorizedComments Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe
